GLP-1RAs Linked to Lower Risk for Cirrhosis in Patients with MASLD, Type 2 Diabetes: Daily Dose
Your daily dose of the clinical news you may have missed.
Cannabis: An "Ins and Outs" Primer for Primary Care
A concise update on legal status, FDA approvals, patient safety, and public perception.
Once-a-Week Insulin Matches Daily Insulin in Lowering HbA1c: Daily Dose
US Drug Overdose Deaths Declined in 2023 for the First Time in 5 Years, CDC Reports
The 3% decline in 2023 compared with 2022 is "heartening news," CDC's Houry says, but the mission is far from accomplished.
Blood-Based Test May be Effective Option for Colorectal Cancer Screening in Average-Risk Adults
DDW 2024. An investigational blood-based screening test demonstrated nearly a 80% sensitivity for detecting CRC, according to a large prospective study.
Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes
Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.
Drug Use in the US: Best and Worst States in 2024
Which state has the lowest percentage of teen drug users? Or the highest percentage of adults with unmet drug-treatment needs? Answers from a new report, here.
Higher Prepregnancy BMI Category Linked to Increase in Poor Maternal and Neonatal Outcomes
Women with class 3 obesity before becoming pregnant have up to a 4.5-fold greater risk of composite maternal morbidity that includes preeclampsia, preterm delivery, DM.
Children of Parents with Obesity or Overweight Face Increased Risk of MASLD Later in Life
DDW 2024. Offspring with both parents with overweight had a nearly 3-fold increased risk of MASLD in young adulthood, according to new data.
Risk of Diabetes-related Complications Higher in Men than Women: Daily Dose
COVID-19 Infection in Second Trimester May Increase Risk of Preeclampsia, New Study Finds
Data presented at ACOG 2024 suggest SARS-CoV-2 infection early in pregnancy can lead to a higher likelihood of preeclampsia, as well as more severe disease.
Dupilumab in Replicate Phase 3 Trial Significantly Reduces COPD Exacerbations, Improves Lung Function, with PDUFA Date in Sight
Dupilumab reduced COPD exacerbations by 34% in adults with uncontrolled symptoms and evidence of T2 inflammation, and significantly improved lung function.
GLP-1 Agonists Reduce Risk of Cirrhosis, HCC in Adults with MASLD and T2D
DDW 24. New research shows patients with MASLD and T2D who used GLP-1 agonists had a reduced risk of progression to cirrhosis and HCC vs non-users.
Irregular Menstrual Cycle Linked to Cardiometabolic Conditions Regardless of PCOS Status: Daily Dose
Tezepelumab Cuts COPD Exacerbation Rate in High-Risk Population: COURSE Trial Highlights with Dave Singh, MD
Dave Singh, MD, lead investigator for the phase 2a COURSE trial of tezepelumab in moderate to very severe COPD, highlights the drug's promise in vulnerable groups.
Tezepelumab Reduces Rate of COPD Exacerbations in Individuals with Wide Range of Blood Eosinophil Levels: Phase 2a COURSE Trial Findings
ATS: The biologic shows promise in a range of people with COPD, particularly those with BEC levels of 150 cells/μL and greater, according to findings released at the 2024 ATS meeting.
ETHOS Post-Hoc Analysis: Dave Singh, MD, Highlights Breztri Reduction of Cardiopulmonary Risk in COPD
The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.
New Study Shows Men with Diabetes Have Higher Risk of Disease-related Complications than Women
Men with diabetes had a greater risk of CVD, lower limb and kidney complications, and diabetic retinopathy compared to women with diabetes.
Vaping, Drinking Before Pregnancy Not Tied to Higher Risk of Miscarriage: Daily Dose
Menopausal VMS Severity, Frequency Reduced Significantly with Elinzanetant: Bayer Shares Data from Pivotal OASIS 1 and 2 Trials
The 2 phase 3 trials met all primary and secondary endpoints, showing statistically significant reduction in symptoms and sleep disturbance and improvement in quality of life.
